Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-up Study of SAT-3247 in DMD
NCT06867107Phase 2Enrolling by invitation
- Sponsor
- Satellos Bioscience Inc.
- Start
- Aug 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of forazapadin in Duchenne muscular dystrophy (DMD), sponsored by Satellos Bioscience Inc. Primary endpoints: Treatment emergent adverse events at 12 months and SAT-3247 effect on fat fraction in biceps brachii at 12 months. Started Aug 2025; status: enrolling by invitation.
02
Drugs
forazapadin
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06867107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867107.